Medication info
Glymepride 4 mg Tablet (Glymepride)

Glymepride 4 mg Tablet (Glymepride)

Prescription medicationTabletOral
Ingredient · strength
Glimepiride›4mg / 1 tablet
Manufacturer / importer
Gunil Biopharm Co., Ltd.
Appearance
Light blue rectangular tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 201903381 · Approved 2019.05.24 · Insurance code 073000880

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
Adjust the dose individually for each patient. Swallow without chewing with at least 1/2 cup of water. This medicine is administered orally once daily. Take this medicine before breakfast or immediately before the first meal. It is very important not to skip a meal after taking this medicine. 1. Monotherapy 1) Initial dose and dose titration In patients who have not previously received medication, initiate treatment with glimepiride 1 mg once daily. If necessary, increase the dose by 1 mg at intervals of 1 ~ 2 weeks. In general, doses above 4 mg provide little additional benefit, although some patients have achieved better metabolic control with doses increased to 6 mg (or 8 mg). If treatment with 4 mg once daily is unsuccessful, first consider switching to insulin therapy; otherwise, consider combination therapy with insulin or another oral antidiabetic drug. 2) Subsequent dose adjustment As diabetes control improves during treatment, the need for this medicine may decrease. Therefore, dose reduction or discontinuation of this medicine may be necessary to avoid hypoglycemia. Dose adjustment should also be considered if weight loss, lifestyle changes, or other factors that may increase the risk of hypoglycemia or hyperglycemia occur. 3) Switching from another oral blood glucose-lowering agent to this medicine There is no precise dose-equivalence relationship between this medicine and other oral blood glucose-lowering agents. When switching from another oral blood glucose-lowering agent to this medicine, it is advisable to follow the method described under Initial dose. That is, initiate treatment with 1 mg once daily and adjust the dose at intervals of 1 ~ 2 weeks. Consider the potency and duration of action of the previously administered drug. 4) Dose adjustment during treatment While taking this medicine, measure blood glucose and/or urine glucose levels regularly; regular measurement of glycated hemoglobin (HbA1c) levels is also recommended. In general, hypoglycemia can be promptly controlled by immediately taking sugar. Hypoglycemia may recur even after it has been successfully managed initially during treatment with a sulfonylurea. Therefore, patients should be monitored closely. Severe hypoglycemia requires immediate treatment and follow-up by a physician and sometimes hospitalization. 2. Combination therapy 1) Combination therapy with insulin Combination therapy with this medicine and insulin is used in patients with secondary failure and when fasting blood glucose (FBG) exceeds 150 mg/dL. Administer 8 mg of this medicine once daily with the first meal, and initiate insulin at a low dose, increasing it approximately weekly according to fasting blood glucose measurements. Once stabilized, capillary blood glucose should be monitored daily whenever possible. The insulin dose should be adjusted periodically while measuring blood glucose and glycated hemoglobin. 2) Combination therapy with metformin If the patient does not respond adequately to the maximum dose of this medicine, addition of metformin may be considered. Clinical information has been published on combination therapy of metformin with other sulfonylureas, such as glibenclamide, glipizide, chlorpropamide, and tolbutamide. When this medicine is used in combination with metformin, the desired blood glucose level may be achieved by adjusting the dose of each drug. However, efforts should be made to determine the minimum effective dose of each drug for blood glucose control. There is a risk of hypoglycemia with concomitant administration of this medicine and metformin, and the risk may increase. Appropriate caution should be exercised.

Ingredients

Manufacturer
Gunil Biopharm Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication is used to assist in blood sugar control for patients with type 2 diabetes, along with dietary and exercise therapy. It may be administered alone, or in cases where blood sugar is not adequately controlled, it can be combined with other oral hypoglycemic agents or insulin. For instance, when regulation is difficult with sulfonylureas or metformin alone, combining metformin with this medication can enhance treatment efficacy. Ultimately, this medication is effectively used to improve blood sugar control.

How to take

Adult dose

Adjust the dose individually for each patient. Swallow without chewing with at least 1/2 cup of water. This medicine is administered orally once daily. Take this medicine before breakfast or immediately before the first meal. It is very important not to skip a meal after taking this medicine. 1. Monotherapy 1) Initial dose and dose titration In patients who have not previously received medication, initiate treatment with glimepiride 1 mg once daily. If necessary, increase the dose by 1 mg at intervals of 1 ~ 2 weeks. In general, doses above 4 mg provide little additional benefit, although some patients have achieved better metabolic control with doses increased to 6 mg (or 8 mg). If treatment with 4 mg once daily is unsuccessful, first consider switching to insulin therapy; otherwise, consider combination therapy with insulin or another oral antidiabetic drug. 2) Subsequent dose adjustment As diabetes control improves during treatment, the need for this medicine may decrease. Therefore, dose reduction or discontinuation of this medicine may be necessary to avoid hypoglycemia. Dose adjustment should also be considered if weight loss, lifestyle changes, or other factors that may increase the risk of hypoglycemia or hyperglycemia occur. 3) Switching from another oral blood glucose-lowering agent to this medicine There is no precise dose-equivalence relationship between this medicine and other oral blood glucose-lowering agents. When switching from another oral blood glucose-lowering agent to this medicine, it is advisable to follow the method described under Initial dose. That is, initiate treatment with 1 mg once daily and adjust the dose at intervals of 1 ~ 2 weeks. Consider the potency and duration of action of the previously administered drug. 4) Dose adjustment during treatment While taking this medicine, measure blood glucose and/or urine glucose levels regularly; regular measurement of glycated hemoglobin (HbA1c) levels is also recommended. In general, hypoglycemia can be promptly controlled by immediately taking sugar. Hypoglycemia may recur even after it has been successfully managed initially during treatment with a sulfonylurea. Therefore, patients should be monitored closely. Severe hypoglycemia requires immediate treatment and follow-up by a physician and sometimes hospitalization. 2. Combination therapy 1) Combination therapy with insulin Combination therapy with this medicine and insulin is used in patients with secondary failure and when fasting blood glucose (FBG) exceeds 150 mg/dL. Administer 8 mg of this medicine once daily with the first meal, and initiate insulin at a low dose, increasing it approximately weekly according to fasting blood glucose measurements. Once stabilized, capillary blood glucose should be monitored daily whenever possible. The insulin dose should be adjusted periodically while measuring blood glucose and glycated hemoglobin. 2) Combination therapy with metformin If the patient does not respond adequately to the maximum dose of this medicine, addition of metformin may be considered. Clinical information has been published on combination therapy of metformin with other sulfonylureas, such as glibenclamide, glipizide, chlorpropamide, and tolbutamide. When this medicine is used in combination with metformin, the desired blood glucose level may be achieved by adjusting the dose of each drug. However, efforts should be made to determine the minimum effective dose of each drug for blood glucose control. There is a risk of hypoglycemia with concomitant administration of this medicine and metformin, and the risk may increase. Appropriate caution should be exercised.

Precautions

This medication should not be used in patients with insulin-dependent diabetes, diabetic ketoacidosis, or those in a coma. Additionally, patients who have had allergic reactions to this medication, sulfonylureas, or sulfonamides should avoid taking it. There is no experience using this medication in patients with severe liver or kidney impairment; in such cases, switching to insulin therapy is recommended. It is best to avoid this medication in women who are pregnant or may become pregnant, as well as those who are breastfeeding. Patients with severe infections, post-surgery, or those with significant trauma are advised to use insulin therapy, and patients with gastrointestinal disturbances such as diarrhea or vomiting should also exercise caution due to the risk of hypoglycemia. This medication contains lactose, so it should be avoided in patients with lactose intolerance or related genetic disorders. During the first week of use, the risk of hypoglycemia is high, so blood sugar should be checked frequently, and symptoms should be closely monitored. Particularly in the elderly, patients with poor nutritional status or irregular eating patterns, those who consume alcohol heavily, patients with weakened liver or kidney function, or those with endocrine disorders, careful observation is even more critical. Symptoms of hypoglycemia may include headache, severe hunger, fatigue, dizziness, confusion, decreased consciousness, etc., and if these symptoms occur, immediate intake of sugar is required. This medication lowers blood sugar levels, so interactions with other drugs may affect blood sugar control. Particularly caution is needed when taken in conjunction with beta-blockers, clonidine, alcohol, antibiotics, and steroid medications. Women who are pregnant or breastfeeding are advised to switch to insulin therapy to avoid effects on the fetus or neonate. In children under 18 years old, safety and efficacy have not been established, so use of this medication is not recommended. Elderly patients often have reduced kidney function, so caution in dose adjustment is necessary. In cases of overdose, hypoglycemia may worsen, so immediate medical attention should be sought for appropriate treatment. This medication should be kept out of reach of children and stored in its original container to maintain its quality.

Side effects

Hypoglycemia, headache, severe hunger, nausea, vomiting, fatigue, sleep, sleep disturbances, anxiety, aggression, decreased concentration, decreased agility or energy, depression, confusion, speech abnormalities, aphasia, visual impairment, tremors, incomplete paralysis, sensory disturbances, dizziness, weakness, loss of self-control, temporary mental confusion, seizures, drowsiness, loss of consciousness, coma, shallow breathing, bradycardia, sweating, cold and clammy skin, tachycardia, hypertension, palpitations, angina, deep vein thrombosis, blurred vision, feeling of fullness or pressure in the upper abdomen, abdominal pain, diarrhea, increased liver enzymes, liver dysfunction, bile secretion disorders, jaundice, hepatitis, thrombocytopenia, leukopenia, hemolytic anemia, erythrocytopenia, agranulocytosis, pancytopenia, itching, hives, rash, difficulty breathing, hypotension, shock, anaphylaxis, angioedema, Stevens-Johnson syndrome, allergic vasculitis, photosensitivity reactions of the skin, decreased serum sodium concentration, taste disorders, hair loss, weight gain, dizziness, liver dysfunction, abdominal pain, arthralgia, indigestion, facial swelling, erectile dysfunction, facial flushing, gastritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air or moisture, and it is best stored at a temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness over an extended period.

Appearance and packaging

Appearance

Light blue rectangular tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.